396 related articles for article (PubMed ID: 18160621)
1. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
Falconar AK
Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
[TBL] [Abstract][Full Text] [Related]
2. Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies.
Falconar AK
BMC Res Notes; 2012 Jul; 5():208. PubMed ID: 22546090
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
[TBL] [Abstract][Full Text] [Related]
4. Serotype-specific anti-Dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production.
Masrinoul P; Omokoko MD; Pambudi S; Ikuta K; Kurosu T
Viral Immunol; 2013 Aug; 26(4):250-8. PubMed ID: 23941673
[TBL] [Abstract][Full Text] [Related]
5. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
[TBL] [Abstract][Full Text] [Related]
6. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis.
Falconar AK
Arch Virol; 1997; 142(5):897-916. PubMed ID: 9191856
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1).
Gelanew T; Poole-Smith BK; Hunsperger E
J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890
[TBL] [Abstract][Full Text] [Related]
8. [To evaluate the neutralizing abilities of anti-dengue virus antibodies with nonstructural protein 1 antigen capture enzyme-linked immunosorbent assay].
Wen K; Ding YQ; Qiu LW; Pan YX; Cai JP; Yue CF; DI B; Che XY
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):680-5. PubMed ID: 20021846
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
Hiramatsu K; Tadano M; Men R; Lai CJ
Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design.
Falconar AK
Clin Vaccine Immunol; 2007 May; 14(5):493-504. PubMed ID: 17329445
[TBL] [Abstract][Full Text] [Related]
11. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.
Gromowski GD; Roehrig JT; Diamond MS; Lee JC; Pitcher TJ; Barrett AD
Virology; 2010 Nov; 407(2):237-46. PubMed ID: 20832836
[TBL] [Abstract][Full Text] [Related]
12. Use of synthetic peptides to represent surface-exposed epitopes defined by neutralizing dengue complex- and flavivirus group-reactive monoclonal antibodies on the native dengue type-2 virus envelope glycoprotein.
Falconar AKI
J Gen Virol; 2008 Jul; 89(Pt 7):1616-1621. PubMed ID: 18559931
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
Gelanew T; Hunsperger E
Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
[TBL] [Abstract][Full Text] [Related]
14. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
Gromowski GD; Barrett AD
Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
[TBL] [Abstract][Full Text] [Related]
17. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
18. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.
Falconar AK
Arch Virol; 1999; 144(12):2313-30. PubMed ID: 10664386
[TBL] [Abstract][Full Text] [Related]
19. The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease.
Falconar AK; Martinez F
PLoS One; 2011; 6(6):e21024. PubMed ID: 21731643
[TBL] [Abstract][Full Text] [Related]
20. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.
Goncalvez AP; Men R; Wernly C; Purcell RH; Lai CJ
J Virol; 2004 Dec; 78(23):12910-8. PubMed ID: 15542643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
